A validation study of the CirCom comorbidity score in an English cirrhosis population using the Clinical Practice Research Datalink by Crooks, Colin J. et al.
© 2018 Crooks et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. 
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work 
you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For 
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Clinical Epidemiology 2018:10 107–120
Clinical Epidemiology Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
107
O R I G I N A L  R E S E A R C H
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/CLEP.S147535
A validation study of the CirCom comorbidity 
score in an English cirrhosis population using the 
Clinical Practice Research Datalink
Colin J Crooks1,2
Joe West1,2
Peter Jepsen3,4
1Division of Epidemiology and Public 
Health, University of Nottingham, 
Nottingham, UK; 2Nottingham 
Digestive Diseases Biomedical 
Research Centre, School of 
Medicine, University of Nottingham, 
Nottingham, UK; 3Department of 
Hepatology and Gastroenterology, 
Aarhus University Hospital, Aarhus, 
Denmark; 4Department of Clinical 
Epidemiology, Aarhus University 
Hospital, Aarhus, Denmark
Purpose: The CirCom score has been developed from Danish data as a specific measure of 
comorbidity for cirrhosis to predict all-cause mortality. We compared its performance with the 
Charlson Comorbidity Index (CCI) in an English cirrhosis population. 
Patients and methods: We used comorbidity scores in a survival model to predict mortal-
ity in a cirrhosis cohort in the Clinical Practice Research Datalink. The discrimination of each 
score was compared by age, gender, socioeconomic status, cirrhosis etiology, cirrhosis stage, 
and year after cirrhosis diagnosis. We also measured their ability to predict liver-related versus 
non-liver-related death.
Results: There was a small improvement in the C statistic from the model using the CirCom 
score (C=0.63) compared to the CCI (C=0.62), and there was an overall improvement in the 
net reclassification index of 1.5%. The improvement was more notable in younger patients, 
those with an alcohol etiology, and those with compensated cirrhosis. Both scores performed 
better (C statistic >0.7) for non-liver-related deaths than liver-related deaths (C statistic <0.6), 
as comorbidity was only weakly predictive of liver-related death.
Conclusion: The CirCom score provided a small improvement in performance over the CCI 
in the prediction of all-cause and non-liver mortality, but not liver-related mortality. Therefore, 
it is important to include a measure of comorbidity in studies of cirrhosis survival, alongside 
a measure of cirrhosis severity.
Keywords: cirrhosis, mortality, comorbidity, prognosis, cause of death, cohort
Plain language summary
 Why was the study done? We assessed whether the effect of non-liver disease on survival in 
patients with liver disease scarring (called cirrhosis) is better captured by a cirrhosis-specific 
measure (the CirCom score) than by a generic measure (the Charlson Comorbidity Index [CCI]).
 What did the researchers do and find? The CirCom score was better able to predict patients’ 
survival times than the CCI, particularly in younger patients, patients with less severe cirrhosis, 
and patients whose cirrhosis was due to alcohol.
 What do these results mean? This paper showed that the CirCom score is better than the 
CCI  at describing the survival of English patients with liver cirrhosis. It also demonstrated the 
importance of accounting for non-liver disease in patients with liver cirrhosis.
Introduction
Patients with cirrhosis have a high mortality.1 Their high mortality is partly due to 
comorbidity,2 so adjustment for differences in the burden of comorbidity is impor-
tant in studies that compare mortality among these patients. This is similar to what 
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has been shown in end-stage renal failure, heart failure, 
and chronic obstructive pulmonary disease (COPD).3–5 For 
cirrhosis, Jepsen et al have developed a comorbidity score 
(CirCom) within a Danish cohort of patients with liver cir-
rhosis and shown it to be an improvement on the existing 
Charlson comorbidity score.6 However, the accompanying 
commentary recommended further external validation that 
included calculation of absolute risks, as well as discrimina-
tion and model fit.7
The most frequently validated method to date is the 
secondary care-derived CCI, published in 1987,8 developed 
using hospital chart data of medical inpatients to predict 
mortality in the 1-year postdischarge and validated in a 
cohort of breast cancer inpatients. However, this score 
assessed all medical inpatients rather than those with spe-
cific disease, thus failing to recognize that the prognostic 
effect of a specific comorbid disease (eg, COPD) might 
depend on the index disease (eg, ischemic heart disease 
versus cirrhosis). Furthermore, the management and prog-
nosis of various diseases have changed greatly over the 
last two decades altering what is relevant to be contained 
in a score. In contrast, CirCom was derived specifically 
for cirrhotic patients and reassessed which comorbidities 
were associated with mortality in this context. It is simpler 
in that it includes less comorbidities overall compared to 
the CCI, but with some different comorbidities such as 
substance abuse (other than alcohol use) and epilepsy.6 We 
have previously extracted a validated and well-described 
cohort of cirrhotic patients with mixed etiology from 
linked primary care, secondary care, and death registry data 
within the Clinical Practice Research Datalink (CPRD).9 
The purpose of this validation study of the CirCom score 
within this English cohort is to assess the performance of 
CirCom compared to the CCI in predicting mortality. By 
doing this assessment, we hope to provide evidence for its 
use (or nonuse) as the preferred measure of comorbidity 
adjustment in future population-based observational studies 
on cirrhosis mortality.
Materials and methods
Dataset
The CPRD consists of linked English Hospital Episodes 
Statistics data, primary care data, and the Office of National 
Statistics (ONS) death register. For this study, these data 
have linked records of all primary care events, hospital 
admissions, and causes of death from April 1997 to August 
2010 for 3% of the English population (244 primary care 
practices).
Population
The cirrhosis cohort we used is one we have previously defined 
from the January 2011 static version of the CPRD (ISAC 
approved protocol number 09_065RA_4 and updated approval 
for this validation study 16_161).9 It consists of 5118 patients 
who were ≥18 years and had a diagnostic code for cirrhosis or 
a therapeutic code for cirrhosis, esophageal varices, or portal 
hypertension within either primary care or secondary care data 
within the CPRD between January 1, 1998 and December 31, 
2009. These dates define the period when the linked data were 
available at the time of the initial study. The presence of cirrhosis 
was validated using secondary care, death registry, and free text 
data.1 The study population was restricted to the 244 practices 
with the primary and secondary care linkages available within 
the January 2011 static version of the CPRD. For this cirrhosis 
cohort, the patient characteristics, etiology of the cirrhosis 
(alcohol, viral/autoimmune/metabolic, or unknown), cause of 
death, and 5-year survival have been well described.1,10 The 
observation period for patients within this cohort commenced 
on the latest of 1) 1 year after each patient’s current registration 
date with an eligible practice, 2) the date that their practice’s 
data were up to research standard, or 3) January 1, 1998, when 
the linkage of the CPRD to secondary care data was first avail-
able. The 1-year cutoff following registration was used to avoid 
including potential prevalent cases who were diagnosed before 
they were observable in the dataset. The period of observation 
in this cohort terminated for each patient on the earliest of 1) 
the date of their death, 2) the date the patient left the practice, 
3) their practice’s last data collection date, 4) the last date of 
the available linkage to secondary care (at the time of the study 
derivation) which was December 31, 2009. Within this obser-
vation period, the start of each patient’s follow-up was defined 
as his or her first Read or ICD 10 code for cirrhosis within the 
observation period. Patients with a diagnosis of cirrhosis before 
the observation period were excluded as the CirCom score was 
defined from comorbidity present at the time of diagnosis of 
cirrhosis. Follow-up for each patient ended at the end of the 
observation period described above.
Ethics 
The CPRD has obtained ethical approval from the National 
Research Ethics Service Committee (NRECS) for all purely 
observational research using anonymized CPRD data. Stud-
ies which do not include patient involvement are reviewed 
for scientific quality by the Independent Scientific Advisory 
Committee for the Medicines and Healthcare Products 
 Regulatory Agency database research. Regulatory approval 
for this study was obtained under approval 16_161.
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Sample size
Studies modeling required sample sizes for complex discrimi-
natory models have indicated that a study like ours requires 
at least 500 deaths, and ideally 1000.11 Two thousand five 
hundred sixty-four deaths occurred within our liver cirrhosis 
cohort within the follow-up time providing sufficient power 
overall. Within the stratified analysis, there were more than 
500 deaths in each of the etiology groups when defined as 
Viral/Autoimmune/Metabolic, Alcoholic, or Unspecified, and 
within each of the age categories defined below.
Comorbidity scores
We defined the CirCom score as described by Jepsen et al.6 
This score defines seven different weighted categories using 
ICD 10 codes. We also defined the CCI8 to provide a com-
parison similar to Jepsen et al’s paper. We used the Read and 
ICD 10 codes for the individual comorbidities that we have 
previously defined for calculating the CCI in linked primary 
and secondary care data within the CPRD.12 The Read codes 
for these comorbidities were also used to define the comor-
bidities for the CirCom score, apart from substance abuse, 
epilepsy, and COPD. For the latter two of these categories, 
we used published code lists from www.clinicalcodes.org,13,14 
and for substance abuse, the Read codes are listed in Table S1. 
All comorbidities were defined using all diagnoses coded in 
the 5 years prior to the cirrhosis diagnosis date as was done 
in Jepsen et al’s original paper.6
Other covariates included etiology, cirrhosis stage, year 
of follow-up, socioeconomic status, age, and gender. For the 
stratified analysis, we used the age bands we published in 
our original cohort (<45, 45–54, 55–64, 65–74, >75 years).10 
Etiology was defined using the previously defined groups in 
the cohort as Alcoholic, Viral/Autoimmune/Metabolic, or 
Unspecified. Cirrhosis stage was defined as compensated or 
decompensated using the Baveno IV criteria already defined 
in the cohort.1 Socioeconomic status was defined by quintile 
of deprivation as measured by the English Indices of Multiple 
Deprivation 2010.15 Each year of follow-up from the first to 
the fifth year after cirrhosis diagnosis was defined, similar 
to our previously published work on comorbidity scores.12 
Finally, we used cirrhosis and non-cirrhosis death outcomes 
as already defined in this cohort from previous work on cause 
of death from the linked ONS Death Registry.10 Specifically, 
we categorized deaths using the main ICD 10 chapter head-
ings of K70–K77, C22, I85, I864, and I982 as liver related. 
This definition included bleeding from gastric and esophageal 
varices and hepatocellular carcinoma. All other ICD 10 codes 
were categorized as a non-liver death.
Statistical analysis
We described the cohort characteristics for each covariate 
to allow a comparison with numbers and proportions with 
the Danish Development cohort. We then fitted a Cox pro-
portional hazards model including age, gender, and either 
the CCI as a categorical variable or the CirCom score as a 
categorical variable as in the Jepsen paper. To compare how 
well the Charlson and CirCom score models fitted the data, 
we calculated the Bayesian information criterion (BIC). This 
measure penalizes the likelihood of the model for the number 
of parameters it includes, and the model with the smaller 
BIC value is more likely to have a better fit. Discrimination 
was measured using the Harrell’s C statistic, with 95% CIs 
calculated using the somersD command in Stata.16 We calcu-
lated the predicted absolute 1-year mortality risk from each 
model using cumulative incidence functions. These absolute 
predicted mortality risks were used to classify patients into 
1-year mortality probabilities of ≤20%, 21%–50%, and ≥51% 
to allow the net reclassification index (NRI) to be calculated. 
These were the categories used to assess the development of 
the CirCom score in the Danish cohort and were chosen to 
be clinically relevant.6
To assess the calibration of the two scores, the observed 
1-year mortality, computed using the Kaplan–Meier method, 
was plotted against the 1-year mortality predicted by the Cox 
model.17 In addition, a decision curve analysis was performed 
assessing the net benefit of using each score compared to not 
using a score. The net benefit is calculated as the difference 
between the true positives (proportion of patients whose 
predicted risk was over a particular threshold who also died 
within 1 year of follow-up) and the false positives (propor-
tion of patients whose predicted risk was over a particular 
threshold who did not die within 1 year of follow-up), for 
thresholds of predicted risk from 0% to 100%.18
A stratified analysis was then performed to assess the 
models’ discrimination by age, gender, socioeconomic sta-
tus, cirrhosis etiology, cirrhosis stage, and follow-up year as 
defined above. A final analysis assessed the models’ discrimi-
nation in predicting liver-related death and non-liver-related 
death separately.
Results
Validation population characteristics
The validation cirrhosis cohort from the CPRD had fewer 
patients than that used in Denmark for the score’s development 
and a shorter median follow-up time (1.9 years compared to 
2.8 years, respectively), but a similar median age (59 years 
compared to 58 years, respectively). The CPRD cohort had a 
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lower proportion with alcohol as an etiology, a lower propor-
tion of men, and a lower mortality. This was despite a higher 
proportion of patients in the CPRD who had a comorbidity 
that contributed to the Charlson or CirCom score (Table 1).
Overall performance of comorbidity 
scores
The full models are shown for comparison in Table 2. The 
CirCom score provided a better model fit than the CCI with 
an improvement in the BIC (Table 2).
Measures of discrimination of the CCI and CirCom score 
models are shown in Table 3 compared to models with age 
and sex alone. Both scores showed an improvement when 
compared to age and sex alone with a small improvement 
in the C statistic from the model using the CirCom score 
compared to the CCI. This was also reflected in the 1.5% 
improvement of the CirCom score over the CCI in classify-
ing 1-year mortality as measured by the categorical NRI 
(see Table 3). The addition of a covariate for decompen-
sated or compensated liver disease further increased the 
Table 1 A comparison of the patient demographics of the Clinical Practice Research Datalink (CPRD) validation cohort and the 
original Danish Patient Registry derivation cohort
Characteristics of the validation cohort CPRD cirrhosis cohort Danish patient registry cohort
Patients (n) Patients (%) Patients (n) Patients (%)
Number of patients 5,118 12,976
Follow-up time (person years) 14,438 40,847
Deaths during follow-up 2564 50.1 8911 68.7
Median follow-up time (years) 1.9 2.8
1-year mortality 1516 29.6 34.5
5-year mortality 2332 45.6 80.5
Mean age (interquartile range) 59.1 49.4–70.0 57.9 50.3–65.3
Female 2153 42.1 4397 33.9
Male 2965 57.9 8579 66.1
Decompensated at presentation 2235 43.7
Etiology
Alcohol 2756 53.9 73.7
Viral/autoimmune/metabolic 1079 21.1
Unknown 1283 25.1
Most prevalent comorbidities
Diabetes without complications 979 19.1 835 6.4
Rheumatological disease 705 13.8 422 3.3
Chronic obstructive pulmonary disease 445 8.7 951 7.3
Congestive cardiac disease 344 6.7 673 5.2
Cerebrovascular disease 256 5.0 720 5.5
Diabetes with complications 252 4.9 813 6.3
Hypothyroidism 250 4.9
Peptic ulcer disease 239 4.7 1579 12.2
Cerebrovascular disease 234 4.6 720 5.5
Renal disease 231 4.5 67 0.5
CirCom score
0 3120 61.0 9841 75.8
1+0 1384 27.0 2143 16.5
1+1 409 8.0 477 3.7
3+0 56 1.1 313 2.4
3+1 147 2.9 136 1.0
5+0 2 0.0 50 0.4
5+1 0 0 16 0.1
Charlson Comorbidity Index
0 2644 51.7 7477 57.6
1 999 19.5 3034 23.4
2 617 12.1 1422 11.0
3 299 5.8 576 4.4
4 200 3.9 208 1.6
5 108 2.1 80 0.6
6 74 1.5 106 0.8
≥7 177 3.5 73 0.6
Note: Cells are left blank where information was not presented in the papers on the original cohort studies.
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 discrimination of the model containing the CirCom score 
(C=0.67, 95% confidence interval [0.66–0.68]). Calibration 
was similar between the two scores (Figure S1). The decision 
curve analysis showed similar results for both scores, with 
a net benefit in true over false positives when the threshold 
used for the predicted risk of 1-year mortality was between 
20% and 60% for both the CCI and the CirCom score 
(Figure S2).
To assess whether the differences in performance were 
due to difference in numbers of parameters, we reassessed 
the CCI score collapsed to 0, 1, 2, 3, 4, and 5 or more. 
This reduced the BIC for the CCI to 40,369, but this was 
still greater than the BIC for the CirCom score (which 
remained the better fit). The discrimination for the CCI 
with only six parameters was not altered (C statistic=0.62 
[0.61–0.63]).
Table 2 Full models with the comorbidity scores in the Clinical Practice Research Datalink validation cohort
Covariate Charlson Comorbidity Index Covariate CirCom score
Hazard ratio 95% CI Hazard ratio 95% CI
<20 years Reference – Reference –
20–29 years 2.43 0.58–10.26 1.90 0.45–8.03
30–39 years 2.56 0.63–10.37 2.06 0.51–8.34
40–49 years 3.26 0.81–13.08 2.66 0.66–10.68
50–59 years 3.66 0.91–14.68 3.11 0.78–12.47
60–69 years 4.01 1.00–16.06 3.63 0.90–14.54
70–79 years 5.74 1.43–23.03 5.27 1.31–21.12
80–89 years 8.10 2.02–32.57 7.22 1.80–29.05
90–99 years 13.89 3.26–59.14 10.80 2.54, 46.01
Female Reference – Reference –
Male 1.28 1.18–1.39 1.24 1.15–1.35
Charlson Comorbidity Index CirCom score
0 Reference – 0 Reference –
1 1.09 0.98–1.21 1+0 1.43 1.31–1.57
2 1.27 1.12–1.43 1+1 1.88 1.64–2.15
3 1.53 1.31–1.79 3+0 2.29 1.67–3.14
4 1.46 1.20–1.77 3+1 2.95 2.44–3.56
5 1.63 1.27–2.09 5+0 13.00 3.24–52.24
6 1.62 1.21–2.17 5+1 No patients with a score of 5+1
7 1.98 1.37–2.87
8 3.09 2.40–3.98
9 4.21 2.73–6.50
10 5.22 2.94–9.25
11 4.23 2.39–7.50
12 1.70 0.55–5.29
13 4.95 2.05–11.99
15 4.46 0.63–31.74
Total patients (N) 5118 5118
BIC 40434 40294
Note: Exponentiated coefficients.
Abbreviations: BIC, Bayesian information criterion; CI, confidence interval.
Table 3 Discrimination of the comorbidity models
Measured parameter Age and sex Age and sex + 
Charlson 
Comorbidity Index
Age and sex + 
CirCom score
C statistic 0.60 0.62 0.63
95% CIs 0.59–0.61 0.61–0.63 0.62–0.64
Mean 1-year predicted mortality risk
1-year predicted mortality risk in patients who survived 28.6% 27.8% 27.7%
1-year predicted mortality risk in patients who died 33.4% 35.1% 35.3%
Net reclassification index (NRI) (£20%, 21%–50%, ≥51%)
NRI (compared to age and sex) NA 6.4% 8.0%
NRI (CirCom versus Charlson index) NA NA 1.5%
Abbreviation: CI, confidence interval; NA, not applicable.
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Stratified analysis
The CirCom score conferred a slight improvement in discrim-
ination over the CCI in younger age groups, particularly in 
the <45-year-old age group (Table 4). Among the subgroups 
defined by cirrhosis etiology, the difference between the CCI 
and the CirCom score was most notable in the subgroup 
with alcoholic cirrhosis (Table 5). Both comorbidity scores 
performed better in those with autoimmune, viral, metabolic, 
or unknown causes, which reflected the older mean age in 
these groups and resultant higher prevalence of comorbidity. 
There was also a slight improvement in discrimination of the 
CirCom score over the CCI in those with compensated cir-
rhosis at presentation, but not in those with decompensated 
cirrhosis. The CirCom score performed better than the CCI 
in the first year of follow-up with similar discrimination in 
the subsequent years (Table 6). Discrimination reduced with 
increasing deprivation, but there was less of a reduction for 
the CirCom score (Table S2).
Both comorbidity scores had identically poor dis-
crimination for liver-related death and identically good 
 discrimination for non-liver-related death. The inclusion of 
a measure of decompensation improved the discrimination 
of a model with either score for liver-related death (Table 7).
Discussion
The CirCom score provided a small improvement in per-
formance over the CCI when used to predict mortality in 
a large, population-based cohort of patients with cirrhosis 
of mixed etiology. Both scores showed good discriminative 
ability to predict deaths not related to the liver, which were 
almost half of the deaths, but poor ability to predict deaths 
related to the liver. However, the purpose of a comorbid-
ity score is to adjust for factors other than the severity of 
cirrhosis and in this context it performs. Both the CCI and 
the CirCom score improved the performance of the model 
over using just demographic information, emphasizing 
Table 4 Age-stratified discrimination of the comorbidity models
Age 
(years)
Patients 
(n)
Patients 
(%)
Charlson 
Comorbidity Index
C statistic
95% CI CirCom score
C statistic
95% CI
<45 827 16 0.58 0.54–0.61 0.62 0.59–0.66
45–54 1182 23 0.54 0.52–0.57 0.56 0.54–0.59
55–64 1300 25 0.57 0.54–0.59 0.58 0.56–0.61
65–74 991 19 0.60 0.57–0.62 0.60 0.58–0.63
>74 818 16 0.57 0.54–0.59 0.56 0.53–0.58
Notes: Each estimate is also adjusted for gender. 
Abbreviation: CI, confidence interval.
Table 5 Etiology- and compensation-stratified discrimination of the comorbidity models
Cirrhosis etiology or 
compensation state at 
start of study
Patients (n) Patients (%) Charlson 
Comorbidity Index
C statistic
95% CI CirCom score
C statistic
95% CI
Alcohol 2756 54 0.57 0.56–0.59 0.59 0.57–0.60
Othera 1079 21 0.64 0.61–0.67 0.65 0.62–0.67
Unknown 1283 25 0.69 0.67–0.71 0.69 0.67–0.71
Compensated 2883 56 0.63 0.62–0.65 0.65 0.63–0.66
Decompensated 2235 44 0.62 0.60–0.63 0.62 0.60–0.64
Notes: aAutoimmune, viral, or metabolic. Each estimate is also adjusted for age and gender.
Abbreviation: CI, confidence interval.
Table 6 Follow-up-stratified discrimination of the comorbidity models
Age band Patients 
(n)
Person 
years
Charlson Comorbidity 
Index
C statistic
95% CI CirCom score
C statistic
95% CI
<1 year 5118 1320183 0.62 0.61–0.64 0.64 0.62–0.65
1–2 years 2963 2019508 0.62 0.58–0.65 0.59 0.56–0.62
2–3 years 2194 2297575 0.63 0.59–0.66 0.65 0.61–0.69
3–4 years 1639 2315506 0.63 0.58–0.68 0.63 0.59–0.68
4–5 years 1217 2163567 0.63 0.58–0.70 0.61 0.56–0.67
Notes: Each estimate is also adjusted for age and gender. 
Abbreviation: CI, confidence interval.
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the importance of including a comorbidity measure in any 
comparative study of cirrhosis survival. In particular, this 
validation study supports the use of the CirCom score as a 
measure of non-cirrhosis-related or all-cause mortality in 
cirrhotic patients in the English population.
The importance of our work is not just that it shows 
the utility of the score in an international context beyond 
Denmark, but that it also shows that the score is translatable 
into other coding systems such as the Read codes used in 
the CPRD. Furthermore, the Danish data use secondary care 
outpatient data for longitudinal comorbidity coding, whereas 
the English data use both linked inpatient secondary care 
and general practitioner primary care comorbidity coding. 
The finding that the score showed a consistent improvement 
over the CCI in this different health care context confirms 
the score’s generalizability, particularly as we demonstrated 
an even greater improvement in the C statistic than in the 
original Danish derivation cohort.
The strengths of this study are that it provides an in-
depth analysis of the performance of the CirCom score 
and the CCI in an English population. The English CPRD 
has extensive linkages, and these have allowed the current 
cohort to be validated and its characteristics comprehensively 
described.1,9,10 Therefore, we are confident of the validity 
of the cirrhosis diagnosis from the primary and secondary 
care data, and the recording of death from the national death 
registry. Furthermore, the recording of comorbidity in the 
CPRD has previously been validated against anonymized 
case records in many studies (myocardial infarction,19,20 
heart failure,21,22 cerebrovascular disease,23–25 dementia,26,27 
respiratory disease,28–30 connective tissue disease,31–34 peptic 
ulcers,35 liver disease,9,36 renal failure,37 cancer,38 leukemia, 
and  lymphoma39), and the sensitivity of definitions improved 
when defined from linked primary and secondary care 
records (eg, diabetes,40,41 cirrhosis,9 and acute myocardial 
infarction42).
The Model for End-Stage Liver Disease and the Child-
Pugh score outperformed both the CCI and the CirCom score 
in predicting cirrhosis survival in a US Veteran cohort,43 and 
the validation in the original CirCom score paper showed the 
same.6 However, these measures depend on laboratory values 
that were not available in the CPRD. We have previously 
shown that it was possible to derive a measure of cirrhosis 
stage using just diagnostic coding within the CPRD,9 and 
including this as a variable for decompensation in our current 
study greatly improved the discrimination for liver-related 
death, and consequently the overall  discrimination of all-
cause mortality for our model with the CirCom score. The 
value of a comorbidity score, therefore, is that it predicts the 
additional non-liver-related outcomes that are not predicted 
by measures of severity of cirrhosis, and it will have benefit 
when added to any measure of cirrhosis severity.
The higher prevalence of comorbidity in the English 
cohort compared to the Danish cohort might reflect the more 
extensive comorbidity coding in a comprehensive primary 
care system in the UK or might reflect the more varied etiol-
ogy of the English cohort, which had a lower proportion with 
alcohol etiology. We have previously shown that those patients 
with a non-alcohol etiology survive longer than those with 
an alcohol etiology, and, therefore, will have had a longer 
period of care in which to develop comorbidities and non-
liver-related deaths.44 Finally, within the English cohort, the 
improvement with the CirCom score over the CCI was most 
noticeable in younger patients and in those with an alcohol 
etiology. This likely reflects the inclusion of epilepsy and sub-
stance abuse that have more importance in a cirrhotic cohort 
because of their association with a more hazardous lifestyle.45
Conclusion
We have validated the CirCom score in the English-linked 
CPRD as a measure of the burden of comorbidity and found 
that its performance is better than the CCI. However, both 
the CCI and the CirCom score improved discrimination 
compared to a model containing only age and sex. This 
emphasizes the importance of including any measure of 
comorbidity in comparative studies of cirrhosis survival.
Table 7 Cause of death–stratified and compensation-stratified discrimination of the comorbidity models
Cause of death Patients 
(n)
Patients 
(%)
Charlson 
Comorbidity Index
C statistic
95% CI CirCom score
C statistic
95% CI
Liver-related death 1301 25 0.56 0.54–0.57 0.56 0.54–0.57
Non-liver-related death 1263 25 0.72 0.71–0.74 0.72 0.71–0.74
Cause of death Patients 
(n)
Patients 
(%)
Including measure of 
decompensation
95% CI Including measure of 
decompensation
95% CI
Liver-related death 1301 25 0.64 0.63–0.66 0.64 0.63–0.66
Non-liver-related death 1263 25 0.73 0.72–0.75 0.73 0.72–0.75
Abbreviation: CI, confidence interval.
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Supplementary materials
Table S1 Read code list for non-alcohol substance misuse
Read code Description
146C.00 Failed heroin detoxification
146E.00 H/O: recreational drug use
146F.00 H/O: drug abuse
1J1.00 Suspected drug abuse
1J10.00 Suspected abuse soft drugs
1J11.00 Suspected abuse hard drugs
1T.00 History of substance misuse
1T0.00 H/O heroin misuse
1T00.00 H/O daily heroin misuse
1T01.00 H/O weekly heroin misuse
1T02.00 Previous history of heroin misuse
1T03.00 H/O infrequent heroin misuse
1T1.00 H/O methadone misuse
1T10.00 H/O daily methadone misuse
1T11.00 H/O weekly methadone misuse
1T13.00 Previous history of methadone misuse
1T2.00 H/O ecstasy misuse
1T20.00 H/O daily ecstasy misuse
1T21.00 H/O weekly ecstasy misuse
1T22.00 H/O infrequent ecstasy misuse
1T23.00 Previous history of ecstasy misuse
1T3.00 H/O benzodiazepine misuse
1T30.00 H/O daily benzodiazepine misuse
1T31.00 H/O weekly benzodiazepine misuse
1T32.00 H/O infrequent benzodiazepine misuse
1T33.00 Previous history of benzodiazepine misuse
1T4.00 H/O amphetamine misuse
1T40.00 H/O daily amphetamine misuse
1T41.00 H/O weekly amphetamine misuse
1T42.00 H/O infrequent amphetamine misuse
1T43.00 Previous history of amphetamine misuse
1T5.00 H/O cocaine misuse
1T50.00 H/O daily cocaine misuse
1T51.00 H/O weekly cocaine misuse
1T52.00 H/O infrequent cocaine misuse
1T53.00 Previous history of cocaine misuse
1T6.00 H/O crack cocaine misuse
1T60.00 H/O daily crack cocaine misuse
1T61.00 H/O weekly crack cocaine misuse
1T62.00 H/O infrequent crack cocaine misuse
1T63.00 Previous history of crack cocaine misuse
1T7.00 H/O hallucinogen misuse
1T73.00 Previous history of hallucinogen misuse
1T8.00 H/O cannabis misuse
1T80.00 H/O daily cannabis misuse
1T81.00 H/O weekly cannabis misuse
1T82.00 H/O infrequent cannabis misuse
1T83.00 Previous history of cannabis misuse
1T9.00 H/O solvent misuse
1T90.00 H/O daily solvent misuse
1T91.00 H/O weekly solvent misuse
1T93.00 Previous history of solvent misuse
1TA.00 H/O barbiturate misuse
1TB0.00 H/O daily major tranquilizer misuse
(Continued)
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Read code Description
1TD.00 H/O opiate misuse
1TD0.00 H/O daily opiate misuse
1TD1.00 H/O weekly opiate misuse
1TD2.00 H/O infrequent opiate misuse
1TD3.00 Previous history of opiate misuse
1TE.00 Uses heroin on top of substitution therapy
1TF.00 Does not use heroin on top of substitution therapy
1V.00 Drug misuse behavior
1V0.00 Misuses drugs
1V00.00 Occasional drug user
1V01.00 Long-term drug misuser
1V02.00 Poly-drug misuser
1V0C.00 Drug addict
1V0E.00 Health problem secondary to drug misuse
1V26.00 Misused drugs in past
1V3.00 Drug injection behavior
1V38.00 Sharing of drug-injecting equipment
1V6.00 Drug-related offending behavior
1V64.00 Illicit drug use
1V65.00 Heroin misuse
1V66.00 Ecstasy misuse
46Q5.00 Urine amphetamine
46Q5.11 Amphetamine in urine
46QA.00 Urine cocaine
63C6.00 Maternal drug abuse
8AA.00 Drug abuse monitoring
8H7x.00 Referral to drug abuse counselor
8HHL.00 Referral to community drug dependency team
8Hh1.00 Self-referral to substance misuse service
E240.11 Heroin dependence
E242.00 Cocaine type drug dependence
E242000 Cocaine dependence, unspecified
E242100 Cocaine dependence, continuous
E242200 Cocaine dependence, episodic
E242300 Cocaine dependence in remission
E242z00 Cocaine drug dependence NOS
E244.00 Amphetamine or other psychostimulant dependence
E244000 Amphetamine or psychostimulant dependence, unspecified
E244100 Amphetamine or psychostimulant dependence, continuous
E244200 Amphetamine or psychostimulant dependence, episodic
E244300 Amphetamine or psychostimulant dependence in remission
E244z00 Amphetamine or psychostimulant dependence NOS
E25.00 Nondependent abuse of drugs
E256.00 Nondependent cocaine abuse
E256000 Nondependent cocaine abuse, unspecified
E256100 Nondependent cocaine abuse, continuous
E256200 Nondependent cocaine abuse, episodic
E256300 Nondependent cocaine abuse in remission
E256z00 Nondependent cocaine abuse NOS
E257.00 Nondependent amphetamine or other psychostimulant abuse
E257000 Nondependent amphetamine/psychostimulant abuse, unspecified
E257100 Nondependent amphetamine/psychostimulant abuse, continuous
E257200 Nondependent amphetamine or psychostimulant abuse, episodic
E257300 Nondependent amphetamine/psychostimulant abuse in remission
E257z00 Nondependent amphetamine or psychostimulant abuse NOS
E259.00 Nondependent mixed drug abuse
(Continued)
Table S1 (Continued)
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Read code Description
E259000 Nondependent mixed drug abuse, unspecified
E259100 Nondependent mixed drug abuse, continuous
E259200 Nondependent mixed drug abuse, episodic
E259300 Nondependent mixed drug abuse in remission
E259z00 Nondependent mixed drug abuse NOS
E25y.00 Nondependent other drug abuse
E25y000 Nondependent other drug abuse, unspecified
E25y100 Nondependent other drug abuse, continuous
E25y200 Nondependent other drug abuse, episodic
E25y300 Nondependent other drug abuse in remission
E25yz00 Nondependent other drug abuse NOS
Eu11212 Heroin addiction
Eu14.00 Mental and behavioral disorders due to use of cocaine
Eu14000 Mental and behavior disorder due to use cocaine: acute intoxication
Eu14100 Mental and behavior disorder due to use of cocaine: harmful use
Eu14200 Mental and behavior disorder due to use of cocaine: dependence syndrome
Eu14211 Drug addiction – cocaine
Eu14300 Mental and behavior disorder due to use of cocaine: withdrawal state
Eu14500 Mental and behavior disorder due to use of cocaine: psychotic disorder
Eu1A.00 Mental and behavioral disorders due to use of crack cocaine
Eu1A000 Mental and behavioral disorders due to use of crack cocaine: acute intoxication
Eu1A100 Mental and behavioral disorders due to use of crack cocaine: harmful use
Eu1Az00 Mental and behavioral disorders due to use of crack cocaine: unspecified mental and behavioral 
disorder
R10B000 Finding of cocaine in blood
SL50100 Heroin poisoning
SL85000 Cocaine poisoning
TJ85000 Adverse reaction to cocaine
U205.11 Overdose – heroin
U608312 Adverse reaction to cocaine
Z1Q6214 Heroin maintenance
ZC16.00 Abuse of drugs to lose weight
ZV11500 Personal history of drug abuse by injection
ZV6D700 Drug abuse counseling and surveillance
Abbreviations: H/O, history of; NOS, not otherwise specified.
Table S2 Socioeconomic status (as per IMD 2010)-stratified discrimination of the comorbidity models
Quintile of socioeconomic 
status
Patients 
(n)
Patients 
(%)
Charlson 
Comorbidity 
Index
C statistic
95% CI CirCom index
C statistic
95% CI
Missing socioeconomic status 19 0.00 0.71 0.48–0.94 0.62 0.36–0.88
1=least deprived 856 0.17 0.63 0.60–0.66 0.64* 0.62–0.67
2 987 0.19 0.65 0.62–0.67 0.64 0.62–0.67
3 986 0.19 0.61 0.59–0.64 0.62 0.60–0.65
4 1059 0.21 0.60 0.58–0.63 0.62 0.59–0.64
5=most deprived 1211 0.24 0.61 0.59–0.63 0.63** 0.61–0.65
Notes: *p=0.03 between discrimination for the Charlson Comorbidity Index and the CirCom score. **p=0.007 between discrimination for the Charlson Comorbidity Index 
and the CirCom score. IMD, The English Indices of Multiple Deprivation 2010.2
Abbreviation: CI, confidence interval.
Table S1 (Continued)
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
86
.1
31
.1
46
.0
 o
n 
15
-J
an
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Epidemiology 2018:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
119
CirCom score in an English cirrhosis population
Figure S1 Calibration plots for observed 1-year mortality from Kaplan–Meier estimates against predicted 1-year mortality from the Cox proportional hazards model from 
the (A) Charlson Comorbidity Index and (B) CirCom score.
Note: Calculated using the stcoxgrp ado program.3
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Figure S2 Decision curve analysis plots for (A) the Charlson Comorbidity Index and (B) the CirCom score.
Note: Calculated using the dca ado program.4
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